ID   ZEB1_HUMAN              Reviewed;        1124 AA.
AC   P37275; B4DJV0; B4DUW9; E9PCM7; F5H4I8; Q12924; Q13800; Q2KJ05; Q5T968;
AC   Q5VZ84; Q8NB68;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 2.
DT   28-JUN-2023, entry version 220.
DE   RecName: Full=Zinc finger E-box-binding homeobox 1;
DE   AltName: Full=NIL-2-A zinc finger protein;
DE   AltName: Full=Negative regulator of IL2;
DE   AltName: Full=Transcription factor 8;
DE            Short=TCF-8;
GN   Name=ZEB1; Synonyms=AREB6, TCF8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8138542; DOI=10.1093/oxfordjournals.jbchem.a124267;
RA   Watanabe Y., Kawakami K., Hirayama Y., Nagano K.;
RT   "Transcription factors positively and negatively regulating the Na,K-ATPase
RT   alpha 1 subunit gene.";
RL   J. Biochem. 114:849-855(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Bachman N.J., Scarpulla R.C.;
RT   "A human zinc finger homeodomain protein homologous to the chicken delta-
RT   crystallin enhancer binding protein, delta EF1.";
RL   Submitted (JUL-1994) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 1-798 (ISOFORM 5).
RC   TISSUE=Brain, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 390-1124.
RX   PubMed=1840704; DOI=10.1126/science.1840704;
RA   Williams T.M., Moolten D., Burlein J., Romano J., Bhaerman R., Godillot A.,
RA   Mellon M., Rauscher F.J. III, Kant J.A.;
RT   "Identification of a zinc finger protein that inhibits IL-2 gene
RT   expression.";
RL   Science 254:1791-1794(1991).
RN   [8]
RP   INVOLVEMENT IN PPCD3.
RX   PubMed=16252232; DOI=10.1086/497348;
RA   Krafchak C.M., Pawar H., Moroi S.E., Sugar A., Lichter P.R., Mackey D.A.,
RA   Mian S., Nairus T., Elner V., Schteingart M.T., Downs C.A., Kijek T.G.,
RA   Johnson J.M., Trager E.H., Rozsa F.W., Mandal M.N.A., Epstein M.P.,
RA   Vollrath D., Ayyagari R., Boehnke M., Richards J.E.;
RT   "Mutations in TCF8 cause posterior polymorphous corneal dystrophy and
RT   ectopic expression of COL4A3 by corneal endothelial cells.";
RL   Am. J. Hum. Genet. 77:694-708(2005).
RN   [9]
RP   SUMOYLATION AT LYS-347 AND LYS-774.
RX   PubMed=16061479; DOI=10.1074/jbc.m504477200;
RA   Long J., Zuo D., Park M.;
RT   "Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates
RT   transcriptional repression of E-cadherin.";
RL   J. Biol. Chem. 280:35477-35489(2005).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-322, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   FUNCTION.
RX   PubMed=19935649; DOI=10.1038/ncb1998;
RA   Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A.,
RA   Waldvogel B., Vannier C., Darling D., zur Hausen A., Brunton V.G.,
RA   Morton J., Sansom O., Schuler J., Stemmler M.P., Herzberger C., Hopt U.,
RA   Keck T., Brabletz S., Brabletz T.;
RT   "The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-
RT   inhibiting microRNAs.";
RL   Nat. Cell Biol. 11:1487-1495(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642; SER-679 AND THR-702, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   FUNCTION.
RX   PubMed=20175752; DOI=10.1042/bj20091578;
RA   Papadopoulou V., Postigo A., Sanchez-Tillo E., Porter A.C., Wagner S.D.;
RT   "ZEB1 and CtBP form a repressive complex at a distal promoter element of
RT   the BCL6 locus.";
RL   Biochem. J. 427:541-550(2010).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH SMARCA4, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=20418909; DOI=10.1038/onc.2010.102;
RA   Sanchez-Tillo E., Lazaro A., Torrent R., Cuatrecasas M., Vaquero E.C.,
RA   Castells A., Engel P., Postigo A.;
RT   "ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF
RT   chromatin-remodeling protein BRG1.";
RL   Oncogene 29:3490-3500(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-679, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-679 AND THR-702, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-493; LYS-504 AND LYS-515, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-493, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-493; LYS-504 AND LYS-515, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-493; LYS-504 AND LYS-515, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-186; LYS-195; LYS-307; LYS-331;
RP   LYS-335; LYS-347; LYS-439; LYS-493; LYS-504; LYS-515; LYS-548; LYS-553 AND
RP   LYS-774, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [25]
RP   STRUCTURE BY NMR OF 583-642.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the homeobox domain from human NIL-2-A zinc finger
RT   protein, transcription factor 8.";
RL   Submitted (APR-2007) to the PDB data bank.
RN   [26]
RP   VARIANTS FECD6 THR-78; ALA-649; PRO-810; PRO-840 AND THR-905.
RX   PubMed=20036349; DOI=10.1016/j.ajhg.2009.12.001;
RA   Riazuddin S.A., Zaghloul N.A., Al-Saif A., Davey L., Diplas B.H.,
RA   Meadows D.N., Eghrari A.O., Minear M.A., Li Y.J., Klintworth G.K.,
RA   Afshari N., Gregory S.G., Gottsch J.D., Katsanis N.;
RT   "Missense mutations in TCF8 cause late-onset Fuchs corneal dystrophy and
RT   interact with FCD4 on chromosome 9p.";
RL   Am. J. Hum. Genet. 86:45-53(2010).
RN   [27]
RP   INVOLVEMENT IN FECD6 AND PPCD3, VARIANT FECD6 HIS-640, CHARACTERIZATION OF
RP   VARIANTS FECD6 THR-78 AND HIS-640, AND VARIANT GLU-525.
RX   PubMed=23599324; DOI=10.1167/iovs.13-11781;
RA   Lechner J., Dash D.P., Muszynska D., Hosseini M., Segev F., George S.,
RA   Frazer D.G., Moore J.E., Kaye S.B., Young T., Simpson D.A., Churchill A.J.,
RA   Heon E., Willoughby C.E.;
RT   "Mutational spectrum of the ZEB1 gene in corneal dystrophies supports a
RT   genotype-phenotype correlation.";
RL   Invest. Ophthalmol. Vis. Sci. 54:3215-3223(2013).
RN   [28]
RP   VARIANTS FECD6 THR-78; ALA-649; SER-696; PRO-810; PRO-840 AND GLY-905,
RP   CHARACTERIZATION OF VARIANTS FECD6 THR-78; ALA-649; SER-696; PRO-810;
RP   PRO-840 AND GLY-905, AND SUBCELLULAR LOCATION.
RX   PubMed=25190660; DOI=10.1167/iovs.14-15247;
RA   Chung D.W., Frausto R.F., Ann L.B., Jang M.S., Aldave A.J.;
RT   "Functional impact of ZEB1 mutations associated with posterior polymorphous
RT   and Fuchs' endothelial corneal dystrophies.";
RL   Invest. Ophthalmol. Vis. Sci. 55:6159-6166(2014).
CC   -!- FUNCTION: Acts as a transcriptional repressor. Inhibits interleukin-2
CC       (IL-2) gene expression. Enhances or represses the promoter activity of
CC       the ATP1A1 gene depending on the quantity of cDNA and on the cell type.
CC       Represses E-cadherin promoter and induces an epithelial-mesenchymal
CC       transition (EMT) by recruiting SMARCA4/BRG1. Represses BCL6
CC       transcription in the presence of the corepressor CTBP1. Positively
CC       regulates neuronal differentiation. Represses RCOR1 transcription
CC       activation during neurogenesis. Represses transcription by binding to
CC       the E box (5'-CANNTG-3'). Promotes tumorigenicity by repressing
CC       stemness-inhibiting microRNAs. {ECO:0000269|PubMed:19935649,
CC       ECO:0000269|PubMed:20175752, ECO:0000269|PubMed:20418909}.
CC   -!- SUBUNIT: Interacts (via N-terminus) with SMARCA4/BRG1.
CC       {ECO:0000269|PubMed:20418909}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20418909,
CC       ECO:0000269|PubMed:25190660}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P37275-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P37275-2; Sequence=VSP_045184;
CC       Name=3;
CC         IsoId=P37275-3; Sequence=VSP_047280;
CC       Name=4;
CC         IsoId=P37275-4; Sequence=VSP_047281;
CC       Name=5;
CC         IsoId=P37275-5; Sequence=VSP_047279, VSP_045184;
CC   -!- TISSUE SPECIFICITY: Colocalizes with SMARCA4/BRG1 in E-cadherin-
CC       negative cells from established lines, and stroma of normal colon as
CC       well as in de-differentiated epithelial cells at the invasion front of
CC       colorectal carcinomas (at protein level). Expressed in heart and
CC       skeletal muscle, but not in liver, spleen, or pancreas.
CC       {ECO:0000269|PubMed:20418909}.
CC   -!- DISEASE: Corneal dystrophy, posterior polymorphous, 3 (PPCD3)
CC       [MIM:609141]: A subtype of posterior corneal dystrophy, a disease
CC       characterized by alterations of Descemet membrane presenting as
CC       vesicles, opacities or band-like lesions on slit-lamp examination and
CC       specular microscopy. Affected patient typically are asymptomatic.
CC       {ECO:0000269|PubMed:16252232, ECO:0000269|PubMed:23599324}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Corneal dystrophy, Fuchs endothelial, 6 (FECD6) [MIM:613270]:
CC       A corneal disease caused by loss of endothelium of the central cornea.
CC       It is characterized by focal wart-like guttata that arise from Descemet
CC       membrane and develop in the central cornea, epithelial blisters,
CC       reduced vision and pain. Descemet membrane is thickened by abnormal
CC       collagenous deposition. {ECO:0000269|PubMed:20036349,
CC       ECO:0000269|PubMed:23599324, ECO:0000269|PubMed:25190660}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the delta-EF1/ZFH-1 C2H2-type zinc-finger
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG62481.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D15050; BAA03646.1; -; mRNA.
DR   EMBL; U12170; AAA20602.1; -; mRNA.
DR   EMBL; AK091478; BAC03673.1; -; mRNA.
DR   EMBL; AK296244; BAG58962.1; -; mRNA.
DR   EMBL; AK300830; BAG62481.1; ALT_FRAME; mRNA.
DR   EMBL; AL158080; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL161935; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL117340; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355148; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW85989.1; -; Genomic_DNA.
DR   EMBL; BC112392; AAI12393.1; -; mRNA.
DR   EMBL; M81699; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS44370.1; -. [P37275-5]
DR   CCDS; CCDS53505.1; -. [P37275-2]
DR   CCDS; CCDS53506.1; -. [P37275-4]
DR   CCDS; CCDS53507.1; -. [P37275-3]
DR   CCDS; CCDS7169.1; -. [P37275-1]
DR   PIR; JX0293; JX0293.
DR   RefSeq; NP_001121600.1; NM_001128128.2. [P37275-5]
DR   RefSeq; NP_001167564.1; NM_001174093.1. [P37275-4]
DR   RefSeq; NP_001167565.1; NM_001174094.1.
DR   RefSeq; NP_001167566.1; NM_001174095.1. [P37275-3]
DR   RefSeq; NP_001167567.1; NM_001174096.1. [P37275-2]
DR   RefSeq; NP_110378.3; NM_030751.5. [P37275-1]
DR   PDB; 2E19; NMR; -; A=586-642.
DR   PDBsum; 2E19; -.
DR   AlphaFoldDB; P37275; -.
DR   SMR; P37275; -.
DR   BioGRID; 112796; 167.
DR   CORUM; P37275; -.
DR   ELM; P37275; -.
DR   IntAct; P37275; 26.
DR   MINT; P37275; -.
DR   STRING; 9606.ENSP00000354487; -.
DR   GlyGen; P37275; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P37275; -.
DR   PhosphoSitePlus; P37275; -.
DR   BioMuta; ZEB1; -.
DR   DMDM; 6166575; -.
DR   EPD; P37275; -.
DR   jPOST; P37275; -.
DR   MassIVE; P37275; -.
DR   MaxQB; P37275; -.
DR   PaxDb; P37275; -.
DR   PeptideAtlas; P37275; -.
DR   ProteomicsDB; 19473; -.
DR   ProteomicsDB; 26586; -.
DR   ProteomicsDB; 55272; -. [P37275-1]
DR   ProteomicsDB; 61322; -.
DR   ProteomicsDB; 65678; -.
DR   Antibodypedia; 12930; 802 antibodies from 45 providers.
DR   CPTC; P37275; 3 antibodies.
DR   DNASU; 6935; -.
DR   Ensembl; ENST00000320985.14; ENSP00000319248.9; ENSG00000148516.23. [P37275-1]
DR   Ensembl; ENST00000424869.6; ENSP00000415961.2; ENSG00000148516.23. [P37275-2]
DR   Ensembl; ENST00000446923.7; ENSP00000391612.2; ENSG00000148516.23. [P37275-5]
DR   Ensembl; ENST00000542815.7; ENSP00000444891.2; ENSG00000148516.23. [P37275-3]
DR   Ensembl; ENST00000560721.6; ENSP00000452787.1; ENSG00000148516.23. [P37275-4]
DR   GeneID; 6935; -.
DR   KEGG; hsa:6935; -.
DR   MANE-Select; ENST00000424869.6; ENSP00000415961.2; NM_001174096.2; NP_001167567.1. [P37275-2]
DR   UCSC; uc001ivs.5; human. [P37275-1]
DR   AGR; HGNC:11642; -.
DR   CTD; 6935; -.
DR   DisGeNET; 6935; -.
DR   GeneCards; ZEB1; -.
DR   HGNC; HGNC:11642; ZEB1.
DR   HPA; ENSG00000148516; Low tissue specificity.
DR   MalaCards; ZEB1; -.
DR   MIM; 189909; gene.
DR   MIM; 609141; phenotype.
DR   MIM; 613270; phenotype.
DR   neXtProt; NX_P37275; -.
DR   OpenTargets; ENSG00000148516; -.
DR   Orphanet; 98974; Fuchs endothelial corneal dystrophy.
DR   Orphanet; 98973; Posterior polymorphous corneal dystrophy.
DR   PharmGKB; PA162409589; -.
DR   VEuPathDB; HostDB:ENSG00000148516; -.
DR   eggNOG; KOG3623; Eukaryota.
DR   GeneTree; ENSGT00950000183208; -.
DR   HOGENOM; CLU_005890_0_1_1; -.
DR   InParanoid; P37275; -.
DR   OMA; ANYINFP; -.
DR   OrthoDB; 4266655at2759; -.
DR   PhylomeDB; P37275; -.
DR   TreeFam; TF331759; -.
DR   PathwayCommons; P37275; -.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   SignaLink; P37275; -.
DR   SIGNOR; P37275; -.
DR   BioGRID-ORCS; 6935; 42 hits in 1184 CRISPR screens.
DR   ChiTaRS; ZEB1; human.
DR   EvolutionaryTrace; P37275; -.
DR   GeneWiki; ZEB1; -.
DR   GenomeRNAi; 6935; -.
DR   Pharos; P37275; Tbio.
DR   PRO; PR:P37275; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P37275; protein.
DR   Bgee; ENSG00000148516; Expressed in calcaneal tendon and 209 other tissues.
DR   ExpressionAtlas; P37275; baseline and differential.
DR   Genevisible; P37275; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0070888; F:E-box binding; ISS:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; TAS:ProtInc.
DR   GO; GO:0048856; P:anatomical structure development; IBA:GO_Central.
DR   GO; GO:0051216; P:cartilage development; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0090103; P:cochlea morphogenesis; IEA:Ensembl.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0048704; P:embryonic skeletal system morphogenesis; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0043616; P:keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045602; P:negative regulation of endothelial cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0010839; P:negative regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0007389; P:pattern specification process; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0010464; P:regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0051150; P:regulation of smooth muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0033081; P:regulation of T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0048752; P:semicircular canal morphogenesis; IEA:Ensembl.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 6.
DR   Gene3D; 1.10.10.60; Homeodomain-like; 1.
DR   InterPro; IPR008598; Di19_Zn-bd.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR24391; HISTONE H4 TRANSCRIPTION FACTOR-RELATED; 1.
DR   PANTHER; PTHR24391:SF17; ZINC FINGER E-BOX-BINDING HOMEOBOX 1; 1.
DR   Pfam; PF00096; zf-C2H2; 4.
DR   Pfam; PF05605; zf-Di19; 1.
DR   SMART; SM00389; HOX; 1.
DR   SMART; SM00355; ZnF_C2H2; 7.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 4.
DR   SUPFAM; SSF46689; Homeodomain-like; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 5.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Corneal dystrophy;
KW   Differentiation; Disease variant; DNA-binding; Homeobox; Isopeptide bond;
KW   Metal-binding; Neurogenesis; Nucleus; Phosphoprotein; Reference proteome;
KW   Repeat; Repressor; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..1124
FT                   /note="Zinc finger E-box-binding homeobox 1"
FT                   /id="PRO_0000047231"
FT   ZN_FING         170..193
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         200..222
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         240..262
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         268..292
FT                   /note="C2H2-type 4; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   DNA_BIND        581..640
FT                   /note="Homeobox; atypical"
FT   ZN_FING         904..926
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         932..954
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         960..981
FT                   /note="C2H2-type 7; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          1..124
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          142..163
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          304..327
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          551..586
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          636..714
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          856..898
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          989..1124
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        31..47
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        77..95
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        570..586
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        656..714
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        860..886
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        989..1004
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1027..1050
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1058..1085
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         31
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62947"
FT   MOD_RES         33
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62947"
FT   MOD_RES         313
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64318"
FT   MOD_RES         322
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         642
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         679
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         686
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64318"
FT   MOD_RES         693
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64318"
FT   MOD_RES         700
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64318"
FT   MOD_RES         702
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         704
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64318"
FT   CROSSLNK        186
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        195
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        307
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        331
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        335
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        347
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT   CROSSLNK        347
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        439
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        493
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        504
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        515
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        548
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        553
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        774
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT   CROSSLNK        774
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..19
FT                   /note="MADGPRCKRRKQANPRRNN -> MK (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047279"
FT   VAR_SEQ         20..87
FT                   /note="VTNYNTVVETNSDSDDEDKLHIVEEESVTDAADCEGVPEDDLPTDQTVLPGR
FT                   SSEREGNAKNCWEDDR -> G (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047280"
FT   VAR_SEQ         87..107
FT                   /note="RKEGQEILGPEAQADEAGCTV -> I (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047281"
FT   VAR_SEQ         87
FT                   /note="R -> TG (in isoform 2 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_045184"
FT   VARIANT         78
FT                   /note="N -> T (in FECD6; no effect on protein expression;
FT                   no effect on nuclear localization; dbSNP:rs80194531)"
FT                   /evidence="ECO:0000269|PubMed:20036349,
FT                   ECO:0000269|PubMed:23599324, ECO:0000269|PubMed:25190660"
FT                   /id="VAR_063759"
FT   VARIANT         90
FT                   /note="G -> R (in dbSNP:rs12217419)"
FT                   /id="VAR_052731"
FT   VARIANT         525
FT                   /note="G -> E (found in a patient with FECD6)"
FT                   /evidence="ECO:0000269|PubMed:23599324"
FT                   /id="VAR_072897"
FT   VARIANT         553
FT                   /note="K -> R (in dbSNP:rs35753967)"
FT                   /id="VAR_031824"
FT   VARIANT         640
FT                   /note="Q -> H (in FECD6; down-regulation of several
FT                   collagen genes expression; dbSNP:rs779148597)"
FT                   /evidence="ECO:0000269|PubMed:23599324"
FT                   /id="VAR_072898"
FT   VARIANT         649
FT                   /note="P -> A (in FECD6; no effect on protein expression;
FT                   no effect on nuclear localization; dbSNP:rs781750314)"
FT                   /evidence="ECO:0000269|PubMed:20036349,
FT                   ECO:0000269|PubMed:25190660"
FT                   /id="VAR_063760"
FT   VARIANT         696
FT                   /note="N -> S (in FECD6; no effect on protein expression;
FT                   no effect on nuclear localization; dbSNP:rs567252241)"
FT                   /evidence="ECO:0000269|PubMed:25190660"
FT                   /id="VAR_072899"
FT   VARIANT         810
FT                   /note="Q -> P (in FECD6; no effect on protein expression;
FT                   no effect on nuclear localization; dbSNP:rs199944415)"
FT                   /evidence="ECO:0000269|PubMed:20036349,
FT                   ECO:0000269|PubMed:25190660"
FT                   /id="VAR_063761"
FT   VARIANT         840
FT                   /note="Q -> P (in FECD6; no effect on protein expression;
FT                   no effect on nuclear localization; dbSNP:rs118020901)"
FT                   /evidence="ECO:0000269|PubMed:20036349,
FT                   ECO:0000269|PubMed:25190660"
FT                   /id="VAR_063762"
FT   VARIANT         905
FT                   /note="A -> G (in FECD6; no effect on protein expression;
FT                   no effect on nuclear localization; dbSNP:rs78449005)"
FT                   /evidence="ECO:0000269|PubMed:25190660"
FT                   /id="VAR_072900"
FT   VARIANT         905
FT                   /note="A -> T (in FECD6)"
FT                   /evidence="ECO:0000269|PubMed:20036349"
FT                   /id="VAR_063763"
FT   CONFLICT        12
FT                   /note="Q -> R (in Ref. 3; BAC03673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        81
FT                   /note="N -> S (in Ref. 3; BAC03673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        84
FT                   /note="E -> K (in Ref. 3; BAC03673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        220
FT                   /note="T -> A (in Ref. 3; BAG62481)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        390
FT                   /note="M -> T (in Ref. 3; BAG62481)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        420
FT                   /note="V -> I (in Ref. 2; AAA20602)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        472
FT                   /note="K -> R (in Ref. 3; BAG58962)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        609
FT                   /note="E -> Q (in Ref. 7; M81699)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        654
FT                   /note="I -> T (in Ref. 2; AAA20602)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        672
FT                   /note="D -> H (in Ref. 7; M81699)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        681
FT                   /note="L -> S (in Ref. 7; M81699)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        775
FT                   /note="K -> T (in Ref. 3; BAG62481)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        793..794
FT                   /note="IP -> KY (in Ref. 3; BAG58962)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        797
FT                   /note="A -> N (in Ref. 3; BAG58962)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        818
FT                   /note="A -> V (in Ref. 3; BAG62481)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        838
FT                   /note="I -> T (in Ref. 3; BAC03673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1066
FT                   /note="E -> G (in Ref. 3; BAC03673)"
FT                   /evidence="ECO:0000305"
FT   HELIX           590..600
FT                   /evidence="ECO:0007829|PDB:2E19"
FT   HELIX           608..618
FT                   /evidence="ECO:0007829|PDB:2E19"
FT   HELIX           622..634
FT                   /evidence="ECO:0007829|PDB:2E19"
SQ   SEQUENCE   1124 AA;  124074 MW;  0A2714CC37C848D1 CRC64;
     MADGPRCKRR KQANPRRNNV TNYNTVVETN SDSDDEDKLH IVEEESVTDA ADCEGVPEDD
     LPTDQTVLPG RSSEREGNAK NCWEDDRKEG QEILGPEAQA DEAGCTVKDD ECESDAENEQ
     NHDPNVEEFL QQQDTAVIFP EAPEEDQRQG TPEASGHDEN GTPDAFSQLL TCPYCDRGYK
     RFTSLKEHIK YRHEKNEDNF SCSLCSYTFA YRTQLERHMT SHKSGRDQRH VTQSGCNRKF
     KCTECGKAFK YKHHLKEHLR IHSGEKPYEC PNCKKRFSHS GSYSSHISSK KCISLIPVNG
     RPRTGLKTSQ CSSPSLSASP GSPTRPQIRQ KIENKPLQEQ LSVNQIKTEP VDYEFKPIVV
     ASGINCSTPL QNGVFTGGGP LQATSSPQGM VQAVVLPTVG LVSPISINLS DIQNVLKVAV
     DGNVIRQVLE NNQANLASKE QETINASPIQ QGGHSVISAI SLPLVDQDGT TKIIINYSLE
     QPSQLQVVPQ NLKKENPVAT NSCKSEKLPE DLTVKSEKDK SFEGGVNDST CLLCDDCPGD
     INALPELKHY DLKQPTQPPP LPAAEAEKPE SSVSSATGDG NLSPSQPPLK NLLSLLKAYY
     ALNAQPSAEE LSKIADSVNL PLDVVKKWFE KMQAGQISVQ SSEPSSPEPG KVNIPAKNND
     QPQSANANEP QDSTVNLQSP LKMTNSPVLP VGSTTNGSRS STPSPSPLNL SSSRNTQGYL
     YTAEGAQEEP QVEPLDLSLP KQQGELLERS TITSVYQNSV YSVQEEPLNL SCAKKEPQKD
     SCVTDSEPVV NVIPPSANPI NIAIPTVTAQ LPTIVAIADQ NSVPCLRALA ANKQTILIPQ
     VAYTYSTTVS PAVQEPPLKV IQPNGNQDER QDTSSEGVSN VEDQNDSDST PPKKKMRKTE
     NGMYACDLCD KIFQKSSSLL RHKYEHTGKR PHECGICKKA FKHKHHLIEH MRLHSGEKPY
     QCDKCGKRFS HSGSYSQHMN HRYSYCKREA EERDSTEQEE AGPEILSNEH VGARASPSQG
     DSDERESLTR EEDEDSEKEE EEEDKEMEEL QEEKECEKPQ GDEEEEEEEE EVEEEEVEEA
     ENEGEEAKTE GLMKDDRAES QASSLGQKVG ESSEQVSEEK TNEA
//
